Axxam S.p.A., a premier provider of integrated early discovery services, and Molecular Health GmbH, a leader in artificial intelligence (AI)-driven development solutions, announced a strategic collaboration on June 4, 2025, to accelerate the identification and validation of novel therapeutic targets across a broad range of therapeutic areas.
The partnership creates synergies to deliver precise and clinically driven disease-to-target and target-to-lead solutions to the pharmaceutical and biotech industry by integrating Molecular Health's digital drug development platform Dataome into DiscoveryMAXX, Axxam's integrated early drug discovery process.
AI-Powered Target Discovery Platform
Dataome curates, integrates and structures molecular, phenotypic and clinical data from public, private and proprietary datasets. Its causal insights support pharmaceutical companies in improving drug development, predicting drug safety, optimizing clinical trials and enabling data-driven investment decisions.
Molecular Health applies advanced AI to analyze holistic complex datasets, helping clients identify novel, high-potential drug targets. These computational predictions can be seamlessly integrated into Axxam's discovery platform, which incorporates decades of expertise in biology, assay development, phenotypic and target-based screening, and compound profiling.
Rigorous Biological Validation
Through this partnership, AI-derived targets undergo rigorous experimental validation using a broad suite of advanced in-vitro technologies, including induced pluripotent stem cell (iPSC)-based models, to ensure biological and disease relevance and translational value.
"Identifying the right target is one of the most critical and challenging steps in drug discovery. At Axxam, we believe that biology-driven validation is key to translating digital assessments and predictions into real-world therapies," said Ciriaco Maraschiello, CEO of Axxam. "This strategic partnership between a biology powerhouse like Axxam and a precision medicine-focused AI company like Molecular Health is enabling a new level of accuracy and efficiency in the early drug discovery process, allowing our clients to make more informed decisions, faster, in both preclinical and clinical development."
Enhanced Drug Development Efficiency
Friedrich von Bohlen, CEO of Molecular Health, emphasized the importance of understanding molecular causalities in drug development. "Understanding molecular causalities and variants in phenotypes, diseases and endotypes is essential for pharma and biotech companies to improve efficiency and success rates in drug development," he said. "The integration of our data/AI-based knowledge, simulations and predictions with Axxam's preclinical biology and chemistry assays and expertise will offer improved and accelerated outcomes in early drug discovery."
Company Capabilities
Axxam S.p.A. is a leading provider of integrated discovery services across the life sciences industry, supporting pharma, biotech companies, start-ups, patient foundations and academic groups from hit identification to lead generation. The company's services include assay development, high-throughput screening, hit validation, hit-to-lead and compound management.
Molecular Health has been a leader in data-driven software technologies for the pharmaceutical and biotechnology industries for more than a decade. The company combines human expertise, rigorous data curation, and advanced analytics to transform biomedical knowledge into actionable insight. Its Pharma AI solutions power indication and biomarker discovery, target identification and validation, clinical-trial design and simulation, endpoint optimization, and safety prediction.
By building a bridge between AI-powered clinical-molecular predictions and biological insight, Axxam and Molecular Health are positioned to deliver next-generation discovery programs to pharmaceutical innovators worldwide.
